14h55 Volney Soares Lima
Propaganda
Imunoterapia em pacientes com câncer de bexiga avançado Dr. Volney Soares Lima Oncocentro BH – Hosp. Felício Rocho - IPSEMG Conflitos de interesse • Astra Zeneca • Janssen • Bayer • Pfizer • Novartis • Astellas "New kid on the block" • Taxa resposta em torno 25%. • Pessoas que respondem normalmente tem respostas duráveis. • Tratamento bem tolerável. • Taxas de sobrevida parecem ser melhores do que a quimioterapia. Heterogeneidade Heterogeneidade do câncer de bexiga Kamat et all Lancet junho 2016 Números Curiosos! • Estudo de peças de RTU identificam apenas 39% das variantes histológicas posteriormente identificadas na cistectomia!! • 44% dos casos de variantes histológicas não são reconhecidos pelos patologistas da comunidade. Kamat et all Lancet junho 2016 Um pouco sobre genética The genome atlas Nature 2014 Subtipos de câncer de bexiga Choi et al Cancer cell 2014 BCG=Imunoterapia Sidi et al Nat Rev Urol 2014 Vírus Oncolítico Câncer de bexiga metastático tto sistêmico Updated Efficacy From IMvigor210: <br />Atezolizumab in Platinum-Treated Locally Advanced/Metastatic Urothelial Carcinoma (mUC) Presented By Robert Dreicer at 2016 ASCO Annual Meeting Efficacy<br />Responses to Atezolizumab by PD-L1 IC Subgroup Presented By Robert Dreicer at 2016 ASCO Annual Meeting Taxa de resposta Terapia segunda linha pós platina Sobrevida 12 meses Efficacy <br />Overall Survival by Subgroups Presented By Robert Dreicer at 2016 ASCO Annual Meeting PDL1 Testing (IC 2/3 vs. 1/2) Loses Ability to Enrich for Response Across Atezolizumab Studies Presented By Elizabeth Plimack at 2016 ASCO Annual Meeting TCGA Subtype II Is Associated With Higher ORR Presented By Jonathan Rosenberg at 2016 ASCO Annual Meeting IMvigor210: TCGA Subtype in mUC Presented By Jonathan Rosenberg at 2016 ASCO Annual Meeting Mutation Load by FoundationOne and Response Presented By Jonathan Rosenberg at 2016 ASCO Annual Meeting Frontline Therapy for UC: Cis-Ineligible Presented By Elizabeth Plimack at 2016 ASCO Annual Meeting Qual a duração ideal da terapia? Future development of PD1 inhibitors in UC Presented By Elizabeth Plimack at 2016 ASCO Annual Meeting OBRIGADO tel 31 988356591 [email protected]
